Current Status and Prospects of Targeted Therapy for Osteosarcoma

被引：60

作者：

Hu, Zunguo ^{[1
]}

Wen, Shuang ^{[1
]}

Huo, Zijun ^{[2
]}

Wang, Qing ^{[3
]}

Zhao, Jiantao ^{[2
]}

Wang, Zihao ^{[1
]}

Chen, Yanchun ^{[2
]}

Zhang, Lingyun ^{[3
]}

Zhou, Fenghua ^{[3
]}

Guo, Zhangyu ^{[3
]}

Liu, Huancai ^{[1
]}

Zhou, Shuanhu ^{[4
]}

机构：

[1] Weifang Med Univ, Affiliated Hosp, Sch Clin Med, Dept Joint Surg, Weifang 261061, Peoples R China

[2] Weifang Med Univ, Sch Basic Med Sci, Dept Histol & Embryol, Weifang 261053, Peoples R China

[3] Weifang Med Univ, Neurol Disorders & Regenerat Repair Lab, Weifang 261053, Peoples R China

[4] Harvard Med Sch, Brigham & Womens Hosp, Dept Orthped Surg, Boston, MA 02115 USA

来源：

CELLS | 2022年 / 11卷 / 21期

关键词：

osteosarcoma; targeted therapy; chemotherapy; surgical treatment; HIGH-GRADE OSTEOSARCOMA; GROWTH-FACTOR RECEPTOR; SOFT-TISSUE SARCOMAS; FACTOR-I RECEPTOR; PHASE-II; METASTATIC OSTEOSARCOMA; PHOTODYNAMIC THERAPY; PROGNOSTIC-FACTORS; LIMB SALVAGE; CANCER;

D O I：

10.3390/cells11213507

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Osteosarcoma (OS) is a highly malignant tumor occurring in bone tissue with a high propensity to metastasize, and its underlying mechanisms remain largely elusive. The OS prognosis is poor, and improving the survival of OS patients remains a challenge. Current treatment methods such as surgical approaches, chemotherapeutic drugs, and immunotherapeutic drugs remain ineffective. As research progresses, targeted therapy is gradually becoming irreplaceable. In this review, several treatment modalities for osteosarcoma, such as surgery, chemotherapy, and immunotherapy, are briefly described, followed by a discussion of targeted therapy, the important targets, and new technologies for osteosarcoma treatment.

引用

页数：19

共 146 条

[41] Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].

Farmer, H ;

McCabe, N ;

Lord, CJ ;

Tutt, ANJ ;

Johnson, DA ;

Richardson, TB ;

Santarosa, M ;

Dillon, KJ ;

Hickson, I ;

Knights, C ;

Martin, NMB ;

Jackson, SP ;

Smith, GCM ;

Ashworth, A .

NATURE, 2005, 434 (7035) :917-921

[42] RETRACTED: Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma (Retracted article. See vol. 15, 2023) [J].

Feng, Wenlong ;

Dean, Dylan C. ;

Hornicek, Francis J. ;

Spentzos, Dimitrios ;

Hoffman, Robert M. ;

Shi, Huirong ;

Duan, Zhenfeng .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12

[43] Osteosarcoma Pathogenesis Leads the Way to New Target Treatments [J].

Fernandes, Isabel ;

Melo-Alvim, Cecilia ;

Lopes-Bras, Raquel ;

Esperanca-Martins, Miguel ;

Costa, Luis .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (02) :1-19

[44] Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1 [J].

Ferrari, Stefano ;

Ruggieri, Pietro ;

Cefalo, Graziella ;

Tamburini, Angela ;

Capanna, Rodolfo ;

Fagioli, Franca ;

Comandone, Alessandro ;

Bertulli, Rossella ;

Bisogno, Gianni ;

Palmerini, Emanuela ;

Alberghini, Marco ;

Parafioriti, Antonina ;

Linari, Alessandra ;

Picci, Piero ;

Bacci, Gaetano .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2112-2118

[45] Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma. [J].

Forrest, Suzanne J. ;

Kinnaman, Michael D. ;

Livingston, J. Andrew ;

Vo, Kieuhoa Tran ;

Merriam, Priscilla ;

Clinton, Catherine ;

Desmith, Kylene ;

Cavanaugh, Kerri ;

Felicetti, Brunella ;

Smith, Simon ;

Dean, Emma ;

Kao, Pei-Chi ;

London, Wendy B. ;

Sweet-Cordero, E. Alejandro ;

Janeway, Katherine A. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[46] Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor [J].

Fu, W. ;

Sharma, S. S. ;

Ma, L. ;

Chu, B. ;

Bui, M. M. ;

Reed, D. ;

Pledger, W. J. .

CELL DEATH & DISEASE, 2013, 4 :e566-e566

[47] Mesenchymal stem cells: a potential targeted-delivery vehicle for anti-cancer drug, loaded nanoparticles [J].

Gao, Zibin ;

Zhang, Linan ;

Hu, Jie ;

Sun, Yongjun .

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2013, 9 (02) :174-184

[48] Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050) [J].

Gaspar, N. ;

Campbell-Hewson, Q. ;

Gallego Melcon, S. ;

Locatelli, F. ;

Venkatramani, R. ;

Hecker-Nolting, S. ;

Gambart, M. ;

Bautista, F. ;

Thebaud, E. ;

Aerts, I. ;

Morland, B. ;

Rossig, C. ;

Canete Nieto, A. ;

Longhi, A. ;

Lervat, C. ;

Entz-Werle, N. ;

Strauss, S. J. ;

Marec-Berard, P. ;

Okpara, C. E. ;

He, C. ;

Dutta, L. ;

Casanova, M. .

ESMO OPEN, 2021, 6 (05)

[49] Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN plus etoposide (ETP) plus ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS). [J].

Gaspar, Nathalie ;

Casanova, Michela ;

Sirvent, Francisco Jose Bautista ;

Venkatramani, Rajkumar ;

Morland, Bruce ;

Gambart, Marion ;

Thebaud, Estelle ;

Strauss, Sandra J. ;

Locatelli, Franco ;

Melcon, Soledad Gallego ;

Canete, Adela ;

Bielack, Stefan S. ;

Rossig, Claudia ;

Aerts, Isabelle ;

Marec-Berard, Perrine ;

Kraljevic, Silvija ;

Hayato, Seiichi ;

He, Cixin ;

Dutcus, Corina E. ;

Campbell-Hewson, Quentin .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[50] Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study [J].

Gaspar, Nathalie ;

Occean, Bob-Valery ;

Pacquement, Helene ;

Bompas, Emmanuelle ;

Bouvier, Corine ;

Brisse, Herve J. ;

Castex, Marie-Pierre ;

Cheurfa, Nadir ;

Corradini, Nadege ;

Delaye, Jessy ;

Entz-Werle, Natacha ;

Gentet, Jean-Claude ;

Italiano, Antoine ;

Lervat, Cyril ;

Marec-Berard, Perrine ;

Mascard, Eric ;

Redini, Francoise ;

Saumet, Laure ;

Schmitt, Claudine ;

Tabone, Marie-Dominique ;

Verite-Goulard, Cecile ;

Le Deley, Marie-Cecile ;

Piperno-Neumann, Sophie ;

Brugieres, Laurence .

EUROPEAN JOURNAL OF CANCER, 2018, 88 :57-66

← 1 2 3 4 5 6 7 8 9 10 →